Public release date: 6-Sep-2012 [ | E-mail | Share ] <\/p>\n
Contact: Cathia Falvey cfalvey@liebertpub.com<\/a> 914-740-2100 Mary Ann Liebert, Inc.\/Genetic Engineering News<\/p>\n New Rochelle, NY, September 6, 2012The naturally occurring cytokine interleukin-18, or IL-18, plays a key role in inflammation and has been implicated in serious inflammatory diseases for which the prognosis is poor and there are currently limited treatment options. Therapies targeting IL-18 could prove effective against inflammatory diseases of the lung including bronchial asthma and chronic obstructive pulmonary disease (COPD), as described in a review article published in Journal of Interferon & Cytokine Research (http:\/\/www.liebertpub.com\/jir<\/a>), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers (http:\/\/www.liebertpub.com<\/a>). The article is available free online at the Journal of Interferon & Cytokine Research website. (http:\/\/www.liebertpub.com\/jir<\/a>) <\/p>\n Tomotaka Kawayama and coauthors from Kurume University School of Medicine, Fukuoka, Japan, University of Ryukyus, Okinawa, Japan, and Frederick National Laboratory for Cancer Research, Frederick, MD, review the growing evidence to support the important role IL-18 has in inflammation and how it may help to initiate and worsen inflammatory disorders such as arthritis, dermatitis and inflammatory diseases of the bowel and immune system. In the article \"Interleukin-18 in Pulmonary Inflammatory Diseases\" (http:\/\/online.liebertpub.com\/doi\/full\/10.1089\/jir.2012.0029<\/a>) they describe the potential benefits of therapies aimed at blocking the activity of IL-18 to treat inflammatory lung disease. <\/p>\n \"This review provides an interesting and thorough summary of the biology and potential application of IL-18 in the setting of inflammatory pulmonary disease,\" says Co-Editor-in-Chief Thomas A. Hamilton, PhD, Chairman, Department of Immunology, Cleveland Clinic Foundation. <\/p>\n ### <\/p>\n About the Journal Journal of Interferon & Cytokine Research (http:\/\/www.liebertpub.com\/jir<\/a>), led by Co-Editors-in-Chief Ganes C. Sen, PhD, Chairman, Department of Molecular Genetics, Cleveland Clinic Foundation, and Thomas A. Hamilton, PhD, is an authoritative peer-reviewed journal published monthly in print and online that covers all aspects of interferons and cytokines from basic science to clinical applications. Journal of Interferon & Cytokine Research is the official journal of the International Society for Interferon and Cytokine Research. Complete tables of content and a sample issue (http:\/\/online.liebertpub.com\/toc\/jir\/31\/6<\/a>) may be viewed online at the Journal of Interferon & Cytokine Research website. (http:\/\/www.liebertpub.com\/jir<\/a>) <\/p>\n About the Publisher <\/p>\n Mary Ann Liebert, Inc., publishers (http:\/\/www.liebertpub.com<\/a>) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Viral Immunology, AIDS Research and Human Retroviruses, and DNA and Cell Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at Mary Ann Liebert, Inc., publishers website. (http:\/\/www.liebertpub.com<\/a>). <\/p>\n<\/p>\n Read this article: <\/p>\n Promising new drug target for inflammatory lung diseases<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Public release date: 6-Sep-2012 [ | E-mail | Share ] Contact: Cathia Falvey cfalvey@liebertpub.com<\/a> 914-740-2100 Mary Ann Liebert, Inc.\/Genetic Engineering News New Rochelle, NY, September 6, 2012The naturally occurring cytokine interleukin-18, or IL-18, plays a key role in inflammation and has been implicated in serious inflammatory diseases for which the prognosis is poor and there are currently limited treatment options. Therapies targeting IL-18 could prove effective against inflammatory diseases of the lung including bronchial asthma and chronic obstructive pulmonary disease (COPD), as described in a review article published in Journal of Interferon & Cytokine Research (http:\/\/www.liebertpub.com\/jir<\/a>), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers (http:\/\/www.liebertpub.com<\/a>). The article is available free online at the Journal of Interferon & Cytokine Research website. Continue reading